PTGX — Protagonist Therapeutics Inc

Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ. It is led by Dinesh V. Patel Ph.D., based in 7707 Gateway Boulevard, Newark, CA, United States, 94560, with about 131 employees. Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Net income was -$85.8M. PTGX currently screens at market cap $7.25B.

Use this PTGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PTGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PTGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Protagonist Therapeutics Inc even when a live quote feed is slow.